Loading…

Surrozen IncSRZNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 94
Mkt cap
$605M
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$8.15M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.6%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$31.74
1D+5.9%
1W-0.4%
1M+26.2%
3M+35.1%
6M+17.3%
YTD+40.4%
1Y+148.1%
ATR %7.8%
Beta1.55
52w lowhigh16.1% off high

What Surrozen does

Employees: 44

Surrozen at a glance

Size Surrozen (SRZN) is a United States Health Care company (Biotechnology) with a market value of $605M, the 2550th largest of 3,085 United States companies the cockpit tracks. Shares closed at $31.74 on 18 Nov 2026.

Performance Over six months the shares gained 17.3%, against -25.6% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 192.1% over the last twelve months (peer median +13.3%); the operating margin is -485.4% (peer median -64.9%).

Valuation It trades at 48.5× enterprise value to sales against a peer median of 3.4× (2nd most expensive of 16).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026SRZN 117Peer median 75
Six months, rebased to 100: Surrozen against the median of its 20 peers (local-currency closes).

Surrozen financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$10.5M$3.48M$10.7M$0$12.5M
Revenue growth—-67%—-100%—
Gross profit$10.3M$2.94M$9.21M-$1.91M$9.23M
EBITDA-$50.9M-$41.6M-$24.1M-$41.1M-$41.1M
Net income-$408M-$242M-$63.6M-$43.0M-$36.0M
Free cash flow-$30.8M-$30.4M-$17.7M-$40.8M-$44.9M
Capital expenditure$225,000$128,000$26,000$398,000$728,000
Total debt$5.84M$6.64M$8.47M$3.38M$5.60M

Quarterly statements and history in the cockpit →

Surrozen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-100%0%+100%+200%+300%0%+50%688639DSGN603387JANXFDMTGERN1672GNFT68819730087199667729SRZN6-month return →1-month return →
Up and to the right = strong over both horizons. Surrozen is the large dot.

Fundamentals: revenue growth against valuation

0%+20,000%+40,000%+60,000%+80,000%0×1,000×6886399637FDMT1672SRZNRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Surrozen is the large dot.

Surrozen competitors and peer comparison

How Surrozen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Surrozen against its 20 peers (data as of 18 Nov 2026)
MeasureSRZNPeer medianRank in peer set
1-month return+26.2%-16.5%2nd highest of 21
6-month return+17.3%-25.6%4th highest of 20
Distance from 52-week high-16.1%-48.2%2nd highest of 21
Revenue growth (TTM)+192.1%+13.3%4th highest of 17
Operating margin-485.4%-64.9%4th lowest of 17
EV / Sales48.5×3.4×2nd most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%3.2×n/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a

Questions

Which companies are Surrozen's closest peers?
The cockpit's peer set: Anhui Huaheng Biotechnology (688639.SS), Design Therapeutics (DSGN), Alebund Pharmaceuticals (Jiangsu) (9637.HK), Getein Biotech (603387.SS), Janux Therapeutics (JANX), Shenzhen Weiguang Biological Products (002880.SZ), 4D Molecular Therapeutics (FDMT), Geron (GERN).
Is Surrozen expensive compared with its peers?
On ev / sales it trades at 48.5× against a peer median of 3.4×, 2nd most expensive of 16 in its peer set.
How has Surrozen stock performed?
Over six months to 18 Nov 2026 the shares returned +17.3% against -25.6% for the median peer; over one year +148.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.